Cationic Silver Chalcogenide Quantum Dots for Deep Tissue Imaging
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current quantum dots face challenges in achieving narrow bandwidth near-infrared (NIR) emissions with high quantum yields, high transfection efficiency, and low cytotoxicity, particularly in the 700-900 nm spectral window, while existing synthesis methods are often complex, expensive, and result in toxic materials.
Innovation Solution
Development of cationic silver chalcogenide quantum dots with mixed coatings, specifically using a combination of polyethyleneimine and 2-mercaptopropionic acid, synthesized in an aqueous medium at room temperature, which enhances quantum yield and cytocompatibility, and allows for efficient transfection and imaging.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If quantum dots are synthesized in organic solvents at high temperatures to achieve high quantum yield and narrow emission bandwidth, then the luminescence properties are improved, but the synthesis process becomes complex, expensive, and results in hydrophobic particles requiring additional surface modification
Solution Approach 1:
The patent changes the synthesis parameters by using aqueous solvents instead of organic solvents and conducting the reaction at room temperature instead of high temperatures (200-400°C). This fundamentally alters the synthesis conditions to achieve the desired quantum dot properties without the complexity of high-temperature organic synthesis and subsequent surface modification steps
Solution Approach 2:
The patent employs a self-assembly approach where the quantum dots automatically form with the desired size distribution and luminescence properties under the aqueous synthesis conditions, eliminating the need for complex post-synthesis surface modification to achieve hydrophilicity and stability
2Manufacturing precision
If conventional quantum dot synthesis methods are used to achieve narrow emission bandwidth, then the luminescence quality is improved, but the quantum dots exhibit cytotoxicity and require additional biocompatible coating steps
Solution Approach 1:
The patent uses room temperature aqueous synthesis instead of high-temperature organic synthesis, which fundamentally changes the chemical environment and results in quantum dots with inherent biocompatibility, eliminating cytotoxicity without requiring additional protective coatings
Solution Approach 2:
The patent converts the potential harm of conventional synthesis methods (cytotoxicity from organic solvents and high temperatures) into a benefit by using aqueous conditions that are inherently biocompatible, transforming the synthesis process to produce quantum dots that are safe for biomedical applications from the outset
3Illumination intensity
If quantum dots are designed to emit in the visible region with high quantum yield, then the luminescence intensity is improved, but they do not penetrate deep into tissue for imaging applications
Solution Approach 1:
The patent changes the emission wavelength parameter by synthesizing quantum dots that emit in the near-infrared region (700-900 nm) instead of the visible region. This parameter change enables deep tissue penetration while maintaining high quantum yield through optimized aqueous synthesis conditions
Solution Approach 2:
The patent creates quantum dots that simultaneously achieve high quantum yield and deep tissue penetration by targeting the near-infrared window, making them universally applicable for both high-intensity luminescence and deep tissue imaging applications
4Device complexity
If aqueous synthesis is used to simplify the synthesis process and improve biocompatibility, then the synthesis complexity is reduced and cytotoxicity is minimized, but the quantum dots exhibit broader size distribution and poorer quantum yield
Solution Approach 1:
The patent optimizes the aqueous synthesis parameters including pH control, temperature maintenance at room temperature, and specific reagent ratios to achieve narrow size distribution and high quantum yield, overcoming the typical limitations of aqueous synthesis methods
Solution Approach 2:
The patent employs controlled synthesis conditions with pH adjustment and monitoring to feedback-control the quantum dot formation process, ensuring consistent size distribution and high quantum yield are achieved throughout the reaction
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The approach results in quantum dots with improved quantum yields up to 150% and enhanced cytocompatibility, suitable for deep tissue imaging and transfection, using sensitive and cost-effective detection methods, while minimizing toxicity.
Implementation Method 1
Quantum Dots (QD) are quantum confined semiconductor nanoparticles. QDs exhibit luminescence properties when excited at a suitable wavelength
Implementation Method 2
a mixed coating wherein the coating comprises of at least 2 different types of materials one being a macromolecule selected from a group of polymers comprising polyethyleneimine
Data Source
AI summary
A novel near-IR emitting cationic silver chalcogenide quantum dot with a mixed coating wherein the coating comprises of at least 2 different types of materials and is capable of luminescence at the desired near IR bandwidth at wavelengths of 800-850 nm. The quantum dot is fabricated via an advantageous single-step, homogeneous, aqueous method at a low temperature resulting a near IR emitting semiconductor quantum dot with high Quantum Yield, high transfection with low toxicity. The quantum dots may be used in medical imaging, tumor detection, drug delivery and labeling as well as in quantum dot sensitized solar cells.